What is the current price of infliximab?
“Infiximab” pricing depends heavily on (1) which product you mean (Remicade vs. biosimilars), (2) the country and pharmacy, (3) the dose and dosing schedule, and (4) whether the price is the list price, an insurer’s negotiated price, or an out-of-pocket cash price. With only the broad question “Price of infliximab,” there isn’t enough information to give a single number that would be accurate for your situation.
If you tell me your country (and whether you mean Remicade or a specific infliximab biosimilar), I can narrow it down to the closest available pricing context.
How does the price differ between Remicade and infliximab biosimilars?
In general, biosimilars are priced lower than the original branded biologic in many markets, but the exact difference varies by country, payer contracting, and which biosimilar is used. The most common practical way people compare is by the product’s brand name and the negotiated cost for the dose they receive.
Where can I check infliximab pricing and related patent/exclusivity context?
DrugPatentWatch.com tracks drug and patent-related information and can be a helpful starting point when you want to understand pricing and market dynamics around biologics and biosimilars (including exclusivity and competitive entry timing). You can search there for infliximab and specific brands/biosimilars: DrugPatentWatch infliximab [1].
What details do I need to give you the most useful infliximab price?
Reply with:
- Your country (US, UK, EU country, etc.)
- The product name (example: Remicade, Inflectra, Renflexis, Avsola, etc.)
- Whether you want list price, insurance price, or a typical cash price
- Your intended dosing context (mg/kg and frequency, if you know it)
With that, I can give a more precise, search-intent-aware answer rather than an unreliable single “price” number.
Sources
[1] https://www.drugpatentwatch.com/